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Abstract X-linked agammaglobulinemia (XLA) is a primary
immunodeficiency disease caused by mutations in the gene
coding for Bruton’s tyrosine kinase (BTK). Deficiency of
BTK leads to a developmental block in B cell differentiation;
hence, the patients essentially lack antibody-producing plas-
ma cells and are susceptible to various infections. A substan-
tial portion of the mutations in BTK results in splicing defects,
consequently preventing the formation of protein-coding
mRNA. Antisense oligonucleotides (ASOs) are therapeutic
compounds that have the ability to modulate pre-mRNA splic-
ing and alter gene expression. The potential of ASOs has been
exploited for a few severe diseases, both in pre-clinical and
clinical studies. Recently, advances have also been made in
using ASOs as a personalized therapy for XLA. Splice-
correction of BTK has been shown to be feasible for different
mutations in vitro, and a recent proof-of-concept study dem-
onstrated the feasibility of correcting splicing and restoring
BTK both ex vivo and in vivo in a humanized bacterial artifi-
cial chromosome (BAC)-transgenic mouse model. This re-
view summarizes the advances in splice correction, as a
personalized medicine for XLA, and outlines the promises
and challenges of using this technology as a curative long-
term treatment option.
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Introduction
Agammaglobulinemias are B cell deficiencies caused by mu-
tations in the genes that encode components of the B cell
receptor (BCR) or its precursor (pre-BCR). X-linked agam-
maglobulinemia (XLA), also known as Bruton’s agamma-
globulinemia, accounts for 85 % of the patients in this group
and is characterized by low or negligible levels of immuno-
globulins [1]. XLAwas first described in 1952 [2] and is often
considered the prototype of an immunodeficiency disease,
since it was the first defect, where a defined immunological
phenotype (lack of gammaglobulin) was identified. In the ear-
ly 1990s, it was demonstrated that the disease was caused by
the inactivation of Bruton’s tyrosine kinase (BTK) [3–5]. Mu-
tations in the BTK gene result in a developmental block in the
bone marrow at the stage where the transition between pro-B
and pre-B cells takes place. In XLA, precursor B cells are
present, but they fail to differentiate [6, 7]. Hence, the amount
of peripheral B cells is low, and they are of an immature
phenotype [8], resulting in the absence of antigen-specific Ig
production [9]. Female carriers are healthy, as the B lympho-
cytes with the X chromosome expressing the wild-type BTK
are specifically selected for; in fact, only a single female with
XLA has been definitively reported [10].
Mouse models have been extensively used to study the
mechanisms of the immunodeficiency, and dysfunction of
the mouse Btk was also identified as the underlying defect
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in mice affected by X-linked immunodeficiency (XID)
[11–13]. This was subsequently confirmed by mouse models
with engineered Btk knockouts (KO), which have essentially
the same phenotype as the XID mice [14–16]. These mice
have a 50 % reduction in the number of splenic B cells and
reduced levels of secretory IgM and IgG3 and impaired re-
sponses to certain T cell-independent antigens [17]. In
humans, the point mutation found in XID mice causes classi-
cal XLA; Btk deficiency therefore results in a less severe
phenotype in mice [18].
XLA patients are vulnerable to bacterial and enteroviral
infections. Encapsulated bacteria such as Haemophilus
influenza and Streptococcus pneumonia are the most typical
causes of bacterial infections [19–23]. Clinically, XLA pa-
tients display infections in the upper and lower respiratory
and gastrointestinal tract [24]. Currently, there is no curative
therapy for XLA, and the treatment instead consists of immu-
noglobulin substitution and frequent administration of antibi-
otics. This is suboptimal [25], since the patients’ quality of life
is reduced owing to recurrent infections [20, 26, 23, 24]. Some
attempts have been made to treat XLA patients by stem cell
transplantation, but the results have not been satisfactory due
to transplantation complications [27]. Therefore, alternative
strategies such as gene therapy remain valid [1, 17]. In this
review, we will briefly discuss one such putative XLA thera-
py, BTK splice-correction, and its possible future applications.
BTK Belongs to a Family of Kinases and Signals
Downstream of the B Cell Receptor
BTK is expressed from a 37.5-kb gene that contains 19 exons
and has a molecular weight of 77 kDa [28–31]. It belongs to
the TEC family of non-receptor kinases (TFKs), consisting of
additional four members: TEC, BMX, ITK, and TXK/RLK
[32]. Among those, BTK and ITK are the only members de-
finitively associated with human disease [33]. While BTK
deficiency causes XLA, mutations inactivating ITK result in-
stead in susceptibility to severe Epstein-Barr virus infections
(reviewed in [34]). ITK is also involved in the formation of a
fusion gene causing T cell lymphomas [35–38]. BTK is
expressed in myeloid cells and in B lineage cells with the
important exception ofmature plasma cells [39–41]. Although
the phenotypic alterations caused by BTK mutations are pre-
dominantly limited to the B cell lineage, there have been re-
ports of other affected cell lineages as well [42, 43].
Similar to other TFKs, BTK has unique domains that are
important for downstream signaling [32]. These are from the
N terminus: pleckstrin homology (PH), Tec homology (TH),
Src homology 3 (SH3), SH2, and the catalytic kinase domain
[42]. Upon BCR stimulation, BTK translocates to the plasma
membrane, where it is phosphorylated at Y551 of the kinase
domain by SRC family kinases. Following the trans-
phosphorylation, BTK becomes auto-phosphorylated at
Y223 in its SH3 domain [44, 45]. BTK subsequently phos-
phorylates phospholipase Cγ2 (PLCγ2), which leads to the
activation of downstream effectors such as NF-κB and in-
creased calcium flux. These events are important for the mat-
uration, survival, and proliferation [42, 46] of B cells, and
BTK-deficient B cells lack the NF-κB auto-regulatory net-
work [47–49].
Mutations in the BTK Gene
More than 800 mutations have been described for BTK. Many
de novo mutations have been reported and no single alteration
accounts for more than 3–6% of all mutations. Genetic chang-
es causing XLA have been identified throughout the BTK
gene with the exception of the SH3 domain, where no mis-
sense mutations have been reported [3, 5, 18, 29, 46, 50, 51].
Common mutations include amino acid substitutions, prema-
ture stop codons, splice site defects, and frameshifts caused by
deletions or insertions. Some mutations, such as amino acid
substitutions in non-invariant sites, and splicing defects, can
result in the expression of low levels of (partially active) BTK,
causing a milder form of XLA [52, 53, 50]. The information
regarding all known mutations in XLA patients has been col-
lected and is available in the BTKbase database (http://
structure.bmc.lu.se/idbase/BTKbase/) [54]. Figure 1 shows
the frequency of different types of BTK mutations from
1252 patients as presented in the BTKbase.
BTK Splice Site Mutations in XLA
A sizeable group of XLA mutations cause splicing defects in
the BTK pre-mRNA. As in most human genes, the open read-
ing frame is not contiguous but is composed of separate exons
disrupted by intronic sequences. These introns must be re-
moved in a precise manner before an mRNA is ready to be
used as template for protein synthesis. This process is carried
out by the spliceosome, a macromolecular machinery, which
is composed of a number of small nuclear RNAs (snRNAs)
Fig. 1 Distribution of the most common type of BTKmutations using an
updated version of BTKbase [54]
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and associated protein complexes [55]. In addition to being
precise, the splicing process also has to be flexible, since over
92 % of all human pre-mRNA transcripts are spliced alterna-
tively to produce different mRNA and protein isoforms from
the same gene [56], often in response to external stimuli. To
achieve this regulation, the spliceosome employs a number of
accessory proteins that can activate, or inhibit, the recognition
of splice sites, such that the combined effect of inhibitors and
activators effectively decides whether a given splice site is
used (Fig. 2a). This flexibility also poses risks, since it can
result in aberrantly spliced transcripts when the pre-mRNA
contains mutations, as in many XLA cases.
As reported by a large number of studies [57, 52, 58–64],
splice site mutations comprise a substantial portion of all mu-
tations causing XLA. These mutations are spread throughout
the gene, and frequently consist of single nucleotide changes,
but may also be caused by insertions or deletions of larger
sequence elements. The mutations occur not only in the in-
variant splice-donor sites or splice-acceptor sites but also in
other intronic or exonic locations. The mechanisms by which
BTK expression is affected also differ. A common type of
mutation disrupts splice sites or weakens enhancer sequences,
which typically results in the exclusion of the whole exon
from the mRNA, even when the mutation only affects one
splice site directly (Fig. 2e). This is due to the fact that, in
the initial phases of the spliceosome assembly, the splice sites
are generally recognized as pairs over the exons (Bexon
definition^), aided by activator proteins that link together the
splicing factors located at the ends of the exon (Fig. 2a) [55].
Conversely, an intronic mutation can create a novel (cryptic)
splice site, causing the inclusion of a cryptic exon (Fig. 2c),
due to exon definition interactions with a splice site-like
Fig. 2 Splicing mechanism and splice correction methods. a Splice sites
are initially recognized by spliceosome components binding to the ends
of the exons (exon definition). The recognition is further regulated by
activating or inhibitory splicing factors. Later, the factors within the
same intron form complexes that excise the intron from the mRNA (not
shown). Different factors are represented using a color code, as indicated.
b–j Effect of mutations on splicing and possible splice correction
methods. On the left side of the panel, splicing of a wild-type pre-
mRNA is depicted schematically (b), followed by mutants with
inclusion of a cryptic exon (c), activation of an alternative, cryptic
splice site (d), and exclusion of a coding exon (e). On the right side of
the panel, different correction methods are depicted for each mutant type,
as indicated by arrows: Blocking the cryptic splice sites with ASOs
restores correct splicing (f, g). Bifunctional ASO recruits splicing
factors to enhance exon recognition (h). Exon inclusion is restored by a
U1 snRNA, which has been modified to better recognize the mutated
splice site (i). Trans-splicing RNA with the correct splice sites replaces
the faulty exon and the splicing machinery recognizes it as the wild-type
exon (j). ASO antisense oligonucleotide, ESE/ESS exonic splicing
enhancer/silencer sequence
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sequence already present in the pre-mRNA (see, e.g., Fig. 3b).
However, both types of mutations can also result in the acti-
vation of alternative splice sites, leading to the inclusion of
intronic sequences as extensions to the coding exons (Fig. 2d),
or exclusions of a portion of an exon. These changes generally
lead to disruption of the reading frame, or possibly in a short-
ened, or lengthened, non-functional BTK protein. Such defec-
tive proteins are expected to be rapidly degraded [50].
Correcting the splicing defects could therefore rescue the ex-
pression of the functional, endogenous BTK protein. These
particular mutations hence form an interesting target group for
personalized RNA therapeutics and are explored in the follow-
ing sections.
Splice Correction Strategies
The strategy required to correct splicing defects depends on
the nature of the mutation in question and is therefore a prime
example of personalized medicine. The correction is most
straightforward for defects caused by the activation of a cryp-
tic splice site (Fig. 2c). Here, splice correction can be achieved
by sterically blocking the access of splicing factors to either
the cryptic splice sites themselves or nearby splicing enhancer
sequences (Fig. 2f, g). In the simplest form, this can be done
by administering short (15–25 nt) antisense oligonucleotides
(ASOs). A number of splicing defects have been corrected
with this methodology using in vivo models [65, 66], includ-
ing hematopoietic cell defects such as beta-thalassemia [67].
An advanced example of this type of therapy are the ASOs
used to correct the reading frame of the DMD mRNA in
Duchenne muscular dystrophy, with clinical studies in phases
II/III completed [68].
The other main type of splicing defect, caused by the ex-
clusion of bona fide exons (Fig. 2e), is a somewhat more
challenging scenario. In some cases, it is possible to find in-
hibitory sites near the affected exons that can be blocked with
simple ASOs, thus relieving the inhibition and allowing more
efficient splicing (e.g., in the treatment of spinal muscular
atrophy (SMA) [69]). However, this may not be the case for
all exons due to lack of such active inhibition. In those cases, it
will be necessary to actively recruit splicing factors that pro-
mote splicing. One way is to use bi-functional oligonucleo-
tides that have an antisense sequence targeting them to the
desired site, as well as an unpaired Btail^ sequence, that is able
to bind splicing activator proteins (Fig. 2h). Currently, this
method remains largely unexplored, although some advances
have been made, e.g., in in vitro SMA models [70].
Another method for enhancing inclusion of skipped exons
is to use modified components of the spliceosome itself. This
can be achieved, for example, by modifying the sequence of
the U1 snRNA, which is the factor involved in recognizing the
5′ splice site (5′ss) of introns, so that its antisense sequence is a
better match to the mutated splice site (Fig. 2i). An even more
exciting method is to use the spliceosome’s capacity to cata-
lyze splicing between two RNA molecules in what is known
as trans-splicing. In this method, an RNA molecule with the
corrected exon sequence is targeted to the affected site and is
then spliced into the maturing mRNA (Fig. 2j). This approach
has the added benefit that it could in principle be used to
correct not only those defects that are caused by splicing errors
but also those caused by missense mutations or even (small)
deletions. However, both the snRNAs and trans-splicing
RNAs must be transcribed from expression vectors and there-
fore require advanced delivery systems. For example, viral
vectors have been used for correction of coagulation factor
deficiency by modified snRNA and trans-splicing in mouse
Fig. 3 Mechanism of splice correction by ASOs for XLA. aMutation in
the intronic region causes the activation of an aberrant splice site, resulting
in an extended exon. ASOs are used to block the exonic splicing enhancer
(ESE) regions or the aberrant splice site in order to restore correct pre-
mRNA splicing. b Intronic mutation activates a cryptic splice site and
introduces a cryptic exon. ASOs blocking the ESEs or the splice sites
restore the correct splicing pattern. The mutated nucleotide is highlighted
in red, and also with an asterisk. ASO antisense oligonucleotide
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models [71, 72]. For the purposes of this review, we will
concentrate on the function of the simpler ASO agents.
Readers interested in the possibilities of using (trans-) RNA-
based correction for XLA are advised to turn to an earlier
recent review of ours [1].
In addition to selecting the optimal RNA target site and
mode of action, the ASO also has to be enhanced for optimal
specificity, stability, and delivery to the target tissues and cells.
The fact that ASOs are chemically synthesized allows for
wide range of chemical modifications that can achieve these
goals. Thesemodifications generally appear either in the sugar
moiety or in the backbone. The most commonly used modifi-
cations are 2′-O-methyl phosphorothioate (2′OMePS),
phosphorodiamidate morpholino oligomer (PMO), locked
nucleic acid (LNA), and 2′-methoxyethoxy (MOE). All of
these modifications provide increased nuclease stability, and
most of them also change the affinity of the ASO for its target
RNA, with LNAmodification giving the strongest increase in
binding affinity [73]. On the flipside, the increased affinity of
LNA may compromise target specificity, and careful optimi-
zation of the specificity is thus required when designing the
ASO [74]. In contrast to the other chemistries, PMO oligo-
mers are charge neutral and are therefore not able to bind to
serum proteins in vivo. This property makes them potentially
less potent at lower doses due to extensive renal clearance
[75]. However, PMOs are extremely well tolerated in vivo
and even repeated doses as high as 1.5 g/kg appear to have
negligible side effects in mice [76]. In order to increase the
potency of PMO oligomers, they have been conjugated to
cell-penetrating peptides (CPPs), which have the ability to
rapidly translocate across cellular membranes, thereby en-
hancing cellular uptake. Different ASO chemistries and CPPs
are reviewed in [77–79].
Recent Advances in Applying Splice Correction Therapies
to XLA Models
While splice correction is a relatively novel therapeutic strat-
egy for XLA, three recent studies by us and others have shown
the feasibility of using ASOs for correcting BTK expression
[80•, 81••, 82•]. In each of these cases, the cause was found to
be an intronic mutation creating a new splice site, namely the
inclusion of a cryptic exon in intron 4 (exon B4a^) (Fig. 3b)
[81••], or activation of new alternative 5′ splice sites (5′ss) in
intron 3, leading to a lengthened exon 3 [80•, 82•] (Fig. 3a). In
the latter case, the two publications described mutations at
almost the exact same site (T to G at 5′ss+108, or C to A at
5′ss+109), both of which resulted in a similar activation of a
cryptic 5′ss. Although the original 5′ss remains intact, prefer-
ential usage of the cryptic sites was observed in both cases.
Interestingly, the T+108G mutation creates a de novo GC-
type 5′ss that are normally present at low frequency (1/100)
in authentic introns [80•]. On further investigation, the cause
behind this preferential activation was revealed to be the pres-
ence of an upstream exonic splicing enhancer (ESE) [80•].
The presence of ESEs was also inferred in our most recent
publication, highlighting the importance of auxiliary elements
for the activation of cryptic splice sites. Furthermore, the two
studies show that blocking enhancer sequences by ASOs was
at least as effective, or more effective, than blocking the core
splice sites [81••, 80•].
The fact that enhancer sequences are also effective targets
increases the available space for optimal ASO design. The
selection of a correct target site is important not only for
ASO efficacy but also for the specificity, in order to avoid
binding to off-target sites in other transcripts. Indeed, it was
found that a PMO ASO was able to block the cryptic splice
site and correct BTK splicing efficiently in primary XLA
PBMCs, even when the PMO had five mismatched positions
[82•]. Thus, while this demonstrates the robustness of splice
correction in vitro in patient cells, it may lead to deleterious
off-target effects in vivo, making it crucial to optimize the
specificity.
To be able to provide a proof of concept for BTK splice
correction in vivo, we turned to mouse models. To our knowl-
edge, there is only one existing transgenic animal model main-
taining a hematopoietic disease caused by aberrant splicing
[83]. In order to more specifically study the feasibility of using
ASOs for human BTK restoration, we generated a transgenic
mouse by using a bacterial artificial chromosome (BAC) con-
struct carrying the human BTK genewith the intron 4mutation
causing XLA. A transgenic mouse was generated by pronu-
clear injection, followed by breeding onto a BtkKO strain. As
a consequence, our model only has the mutated human BTK
and no endogenous mouse Btk. Moreover, the fact that the
BAC construct includes some human genes flanking BTK,
including the splicing factor gene HNRNPH2, adds an addi-
tional human component to our model. Thus, as the only
existing model of its kind, ours is of broad general interest
for studying the treatment strategies for aberrant splicing in
the lymphoid compartment.
The initial phase of the study included the optimization of
the ASOs in vitro. Bioinformatic data about the presence of
putative nearby ESEswas considered for the ASO design. The
most successful ASOs were subsequently tested in the human
transgenic mouse model, initially ex vivo. Since this mouse
model has an XID phenotype, and therefore relatively high
levels of splenic B cells, these cells were isolated for ASO
treatment. We were able to restore BTK mRNA and protein
expression by electroporation of LNA-modified ASOs or by
using cell-penetrating peptide conjugated PMO (CPP-PMO)
both in the mouse primary splenic B cells and in XLA patient
monocytes. We further analyzed the functionality of the re-
stored protein by assessing cell survival and trans-phosphor-
ylation of BTK. Stimulated primary mouse B cells from the
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BAC-transgenic mouse showed phosphorylation of BTK at
Y551 and enhanced survival after ASO treatment, indicating
that BTK was catalytically active and functional.
Importantly, the ex vivo treatment was also able to rescue
BTK in differentiated pro-B cells from the bone marrow (BM)
of the BAC-transgenic mouse. Since XLA patients have the
developmental block at the pro-B cell stage, the ability to target
this cell population is an important indication of the clinical
relevance of the splice correction treatment strategy. As a proof
of concept for in vivo delivery of the splice-correcting ASOs, a
systemic injection to the BAC-transgenic mousewith the CPP-
PMO conjugates was performed. Very encouragingly, after
1 week, BTK was restored in B cells isolated from the spleen
and bone marrow of the in vivo-treated mice. Taken together,
these results demonstrate the feasibility of correcting BTK
defects by ASOs both ex vivo and in vivo, paving the way
for new treatment options for XLA.
Germinal Centers Are Crucial for the Generation
of Pathogen-Specific Plasma Cells
The developmental defect in XLA manifests itself in imma-
ture B cell progenitors, and the treatment therefore needs to
primarily target the defective pro-B cells. In the bone marrow,
proliferating precursor B cells are located mainly in the pe-
riphery, close to the surrounding bone, and intimately associ-
ated with stromal reticular cells [84]. Once the B cell progen-
itors differentiate and reach a more developed stage, they
leave the bone marrow and enter peripheral lymphoid tissues
such as lymph nodes and spleen to undergo maturation in
germinal centers (GCs). More specifically, GCs are the sites
for B cell clonal amplification and somatic hypermutation
(SHM), yielding high affinity antibodies [85]. The GCs attract
naïve B cells, which make up primary follicles in the spleen
and lymph nodes before exposure to antigen. The developing
GC is divided into two distinct compartments, one of which is
the light zone (LZ), where selection of high affinity B cells
take place. This selection is followed by proliferation and
somatic hypermutation in the dark zone (DZ) and subsequent-
ly another round of affinity selection in the LZ [86]. A crucial
component for the GC B cells is the transcription factor Bcl-6,
which regulates and directs their phenotype [87]. This process
is controlled by T follicular helper (Tfh) cells [88] that form a
unique T cell subset, which is also regulated by Bcl-6.
GC B cells may either undergo apoptosis or differentiate
into plasma cells or memory B cells. Plasma cells are commit-
ted to antibody production and they also have the ability to
perform class-switching during maturation [89]. In contrast,
memory B cells form a dormant population are capable of
responding faster once they encounter a former pathogen.
Memory B cells are generated along two unique differentia-
tion pathways, one GC dependent and the other GC
independent. The former cells are somatically mutated and
express high-affinity antibodies, while the latter are not mu-
tated, expressing low-affinity antibodies [90].
From a therapeutical point of view, the restoration of BTK
alone cannot reconstitute the immune system of the XLA pa-
tient. Generation of plasma cells and memory B cells are the
key events for raising an immune response. Since the ASO
therapy provides a transient restoration, additional strategies
supporting the maturation and survival of antibody-producing
B cells are required, such as immunization. Thus, peripheral
lymphoid tissues are the most crucial sites for a supportive
therapy, which will be explored in the following section.
The Treatment Strategy for Splice Correction in XLA
and Future Prospects
The rationale for the splice-correcting treatment strategy in
XLA is to first overcome the differentiation block and gener-
ate mature B cells. The subsequent step is to immunize pa-
tients with the microbes that XLA patients are susceptible to,
with the aim of inducing the formation of long-lived plasma
cells. While plasma cells are end-stage B lineage cells, they
differ considerably from all the earlier stages. Of particular
importance for our treatment concept is the fact that plasma
cells are not dependent on BTK expression. Since plasma cells
can live for several years, a transient treatment of the splicing
defect could ideally generate a long-term immunoprotective
effect. Therefore, the treatment strategy for splice correction in
XLA includes two phases: restoration of BTK followed by
immunization that generates a protective humoral immune
response.
Based on our experiments in transgenic mice carrying the
mutated human BTK gene, we know that B cell progenitors
can be treated ex vivo, thereby restoring BTK protein expres-
sion. Hence, one possibility is to correct pro-B cells ex vivo
and re-infuse them into the patient, where they subsequently
home to the lymphoid tissues (Fig. 4—phase I). Homing of
the injected pro-B cells into the bonemarrow ofmice has been
reported previously [91]. Moreover, intravenous injection of
stem cells to cancer patients for reconstituting the immune
system is used in the clinic, and the injected cells are known
to localize to the bone marrow of the patient. An alternative
method to the ex vivo treatment would be the systemic infu-
sion of ASOs into the patient (Fig. 4—phase I). We have
demonstrated in our experimental model that this is feasible,
i.e., systemic administration of ASOs can restore the expres-
sion of BTK both in the bone marrow and in the spleen of
BTK-defective mice [81••].
Owing to the fact that an infusion would require rather
large amounts of ASOs, an alternative strategy would be to
deliver the ASOs directly into the bone marrow, e.g., into the
back of the pelvic bone (Fig. 4—phase I). This form of
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delivery would lower the cost and could also reduce off-target
effects caused by the uptake into cells outside the bone mar-
row. While these treatments would restore BTK expression in
the progenitor cells, the duration of the expression is crucial,
since the more mature B lineage cells would leave the bone
marrow to home to the secondary lymphoid organs. Thus, at
this point, a secondary phase treatment strategy is needed to
support these cells that would still be dependent onBTK splice
correction for their survival.
The aim of the second phase of the treatment would be to
develop a potent humoral immunity against those infectious
agents to which XLA patients are susceptible (Fig. 4—Phase
II). This will be achieved by immunization using commercial-
ly available vaccines. During vaccination, BTK expression is
required for the survival of the maturing B cells in the periph-
eral lymphoid tissues. The challenge is to reduce the required
amount of ASOs as much as possible. In one scenario, ASOs
would preferentially be delivered locally into the secondary
lymphoid organ, where the immune response takes place.
Let us first consider the immunization. Vaccines are mostly
administered subcutaneously or intramuscularly. However,
given the aim to pursue local administration of ASOs for this
patient category, immunization directly into the lymph nodes
might be a better option, since this is where the immune-
competent cells normally reside. To this end, intra-lymph node
injections have been reported to result in more specific im-
mune responses compared to other administration routes for
the immunotherapy of cancer patients, as well as in allergy
[92–94]. Intra-lymph node injection of antigens has also been
tried in mice [95] with the aim of injecting a biodegradable
vaccine formulation to the lymph nodes through a non-
surgical method [96]. Such delivery vehicles with a controlled
release of antigens into the lymph nodes might thus represent
a future option in the clinic. Moreover, recent evidence indi-
cates that assistance from Tfhs is a limiting factor for vaccine
responses in humans as reviewed in [88]. This also suggests
that manipulation of Tfh cells potentially could boost vaccine
responses, e.g., by reducing the effect of inhibitory signaling
pathways, and such a therapeutic blockade has recently been
reported [97].
In view of these developments, for sustained BTK expres-
sion, ASOs could potentially either be administered into re-
gions that are drained to a particular lymph node or, alterna-
tively, be injected directly into the lymph node. The local
delivery may also be of particular importance in XLA, since
the secondary lymphoid organs are not fully developed in
these patients. This could perhaps also mean that the immuni-
zation may take more time than in healthy individuals, further
increasing the amount of ASOs needed for BTK restoration
during the vaccination. Collectively, the suggested
complementing treatment strategy should theoretically allow
the maturation of B lymphocytes into plasma cells, generating
long-term immune protection.
In our experience, B cells are relatively hard to transfect
with ASOs. Others have also noted the difficulty of delivering
MOE and LNA-modified ASOs to the erythroid progenitor
cells, which are of hematopoietic origin like the B cells [67].
Furthermore, for splice correction, the ASOs also need to be
transported to the nucleus of the cells. For these reasons,
obtaining a meaningful effect would generally require a high
Fig. 4 Proposed treatment options for XLA. The treatment strategy
involves two phases. Phase I is the restoration of BTK expression. In
the ex vivo part, bone marrow cells are collected from the patient. After
the ASO treatment, they are re-injected intravenously (i.v.). In the in vivo
part, ASOs are injected either i.v. or directly into the bone marrow. Phase
II consists of the immunization during sustained expression of BTK. One
possibility is to perform intramuscular vaccination combined with ASO
injection to the lymph node. The other option is to inject both the ASO
and the vaccine into the lymph node. ASO antisense oligonucleotide
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concentration of the ASO. In our hands, most ASO derivatives
were only efficiently taken up by the B cells using electropo-
ration ex vivo. However, since this is a rather harsh method for
the cells, the treatments could likely be improved by alternative
delivery methods. Very promisingly, the PMO oligomers con-
jugated with CPPs gave satisfactory BTK restoration both
ex vivo and in vivo. PMO oligomers with or without CPP
conjugates have also been shown by others to be taken up by
hematopoietic cells both ex vivo and in vivo [67, 98, 99],
suggesting that further development of PMO oligomers with
different CPP conjugates is a promising platform for future
studies. Likewise, further development of other ASO deriva-
tives that are more readily taken up by the B cells may also
provide alternatives for more effective treatments. In this re-
gard, ASOs with mixed LNA/2′OMePS content remain strong
candidates for this development due to their high target affinity.
For the purpose of pre-clinical investigation of ASOs, a
mouse model has its own advantages and disadvantages. Re-
garding the phenotype, our BAC-transgenic model has only a
partial differentiation block as compared to humans, where
essentially no functional B cells are generated. Removing an-
other BTK-related gene, TEC, enhances the disease severity
[100]. Thus, a transgenic mouse model on a BTK/TEC double
KO background is a better disease model for the analysis of
phenotypic changes after the restoration of BTK.Moreover, to
be able to translate the results to the clinics, one might need to
experiment on other animal models, since pharmacokinetic or
pharmacodynamic properties of the ASOs differ between spe-
cies [101]; for example, it is known that mice tolerate CPPs at
higher doses than rats [102].
Conclusion
As for many other genetic diseases, gene therapy represents a
future option for XLA. The transient need of BTK in B cells,
which differentiate into long-lived protective plasma cells,
makes splice correction therapy particularly feasible for
XLA. With our recent report, we have shown the proof of
concept for this type of therapy in XLA. In order to have a
long-term curative effect, BTK restoration needs to be com-
bined with supplementary vaccination strategy. To this end,
optimizing the delivery method for minimal amount of ASOs
and defining the optimal duration for BTK restoration are
crucial parameters to be considered. Thus, the possibility of
targeting B cells and correcting the splicing defects opens up
many options and could potentially be extended to the treat-
ment of other hematopoietic diseases.
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